Mitsubishi UFJ Asset Management Co. Ltd. Boosts Stock Holdings in Abbott Laboratories $ABT

Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in Abbott Laboratories (NYSE:ABT) by 15.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,899,393 shares of the healthcare product maker’s stock after purchasing an additional 935,664 shares during the quarter. Abbott Laboratories accounts for about 0.7% of Mitsubishi UFJ Asset Management Co. Ltd.’s holdings, making the stock its 26th biggest position. Mitsubishi UFJ Asset Management Co. Ltd. owned approximately 0.40% of Abbott Laboratories worth $924,105,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the business. Vanguard Group Inc. raised its position in Abbott Laboratories by 1.8% in the second quarter. Vanguard Group Inc. now owns 172,800,851 shares of the healthcare product maker’s stock worth $23,502,644,000 after acquiring an additional 2,977,715 shares in the last quarter. State Street Corp boosted its holdings in Abbott Laboratories by 0.9% during the second quarter. State Street Corp now owns 78,354,270 shares of the healthcare product maker’s stock worth $10,656,964,000 after buying an additional 689,517 shares in the last quarter. Geode Capital Management LLC increased its holdings in Abbott Laboratories by 3.8% in the second quarter. Geode Capital Management LLC now owns 38,293,067 shares of the healthcare product maker’s stock valued at $5,184,589,000 after buying an additional 1,390,554 shares in the last quarter. Norges Bank acquired a new stake in shares of Abbott Laboratories during the 2nd quarter valued at approximately $3,026,180,000. Finally, Massachusetts Financial Services Co. MA grew its holdings in shares of Abbott Laboratories by 5.8% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 15,096,907 shares of the healthcare product maker’s stock worth $2,022,080,000 after acquiring an additional 821,325 shares during the period. 75.18% of the stock is owned by institutional investors and hedge funds.

Abbott Laboratories Price Performance

Abbott Laboratories stock opened at $114.76 on Thursday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.24 and a current ratio of 1.58. The company has a market cap of $199.42 billion, a price-to-earnings ratio of 30.85, a PEG ratio of 1.82 and a beta of 0.75. Abbott Laboratories has a 1 year low of $105.27 and a 1 year high of $141.23. The firm has a 50 day moving average price of $117.70 and a 200 day moving average price of $125.47.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting analysts’ consensus estimates of $1.50. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The business had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. During the same period in the prior year, the firm posted $1.34 EPS. The business’s revenue for the quarter was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Sell-side analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories’s payout ratio is currently 67.74%.

Insider Activity

In other Abbott Laboratories news, Director Daniel J. Starks acquired 10,000 shares of the firm’s stock in a transaction on Wednesday, February 4th. The stock was bought at an average cost of $108.73 per share, for a total transaction of $1,087,300.00. Following the completion of the purchase, the director directly owned 6,738,817 shares in the company, valued at $732,711,572.41. This represents a 0.15% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.46% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on ABT. Leerink Partners decreased their target price on Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating on the stock in a research report on Friday, January 30th. Sanford C. Bernstein lowered their price objective on shares of Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. BTIG Research cut their target price on shares of Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating for the company in a research report on Tuesday, February 17th. Weiss Ratings lowered shares of Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, January 26th. Finally, Royal Bank Of Canada dropped their price target on Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, Abbott Laboratories presently has an average rating of “Moderate Buy” and an average target price of $137.05.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Fool argues Abbott is a steady income/growth pick, citing double‑digit earnings growth and a reliable dividend that make ABT appealing vs. volatile alternatives — supports income-oriented demand. Forget Tilray: This Steady Income Stock Beats Wild Cannabis Swings Every Time
• Positive Sentiment: Industry report: the genetic testing market is forecast to nearly double by 2033, with Abbott listed among leading players — supports long‑term revenue tailwinds for ABT’s diagnostics business. Genetic Testing Market Competitive Landscape Report 2025
• Positive Sentiment: Cancer diagnostics market report projects robust growth to 2033; Abbott appears as a key participant — positive for recurring, higher‑margin diagnostics revenue over time. Cancer Diagnostics Market Competitive Landscape Report 2025
• Positive Sentiment: Personalized medicine market forecasts strong long‑term expansion; inclusion of Abbott underscores exposure to high‑growth therapeutic and diagnostic trends. Personalized Medicine Market Competitive Landscape Report 2025
• Positive Sentiment: Market note: Abbott “ascends while market falls,” reflecting recent positive intraday/short‑term momentum that can attract tactical buyers. Abbott (ABT) Ascends While Market Falls: Some Facts to Note
• Neutral Sentiment: Barchart asks whether Abbott is underperforming the Nasdaq over the last year; while performance lags, analysts remain optimistic — flags valuation/relative‑performance questions but not new fundamental changes. Is Abbott Laboratories Stock Underperforming the Nasdaq?
• Neutral Sentiment: Valuation piece examines whether recent weakness makes ABT attractively priced; useful context for value investors but provides no fresh catalyst. Is Abbott Laboratories (ABT) Pricing Reflect Long Term Value After Recent Share Price Weakness
• Negative Sentiment: Yahoo analysis on evolving Wall Street narrative notes several research houses have cut price targets (some by US$5–29) and flagged execution/earnings translation risk, creating a split analyst view — this analyst skepticism can pressure multiple and cap near‑term upside. How The Evolving Wall Street Narrative Is Reframing Abbott Laboratories (ABT) Valuation Prospects

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.